IMDNA develops oncology research assays for targeted investigation of genomic alterations, fusion transcripts, gene-expression programs, tumor–immune interactions, signaling pathways, treatment response, resistance, and candidate biomarkers in solid tumors and hematologic malignancies.
Research programs can integrate qPCR/RT-qPCR for targeted DNA/RNA measurements, ELISA for focused quantitative protein biomarker studies, and multiplex bead-based immunoassays for simultaneous cytokine, chemokine, and soluble-protein profiling. Each technology is selected according to the analyte and scientific question rather than treated as interchangeable.
Targeted mutations, fusion transcripts, splice variants, and gene-expression programs.
Oncogenic signaling, DNA repair, apoptosis, proliferation, hypoxia, metabolism, and cellular stress.
Checkpoint biology, inflammatory signaling, immune-cell programs, and immunotherapy-response research.
Leukemia-associated fusions, mutations, expression signatures, and longitudinal molecular studies.
Candidate biomarker verification, experimental treatment response, resistance, and assay development.
Cancer biomarkers include genes, proteins, and other molecular features that may provide information about tumor biology, treatment sensitivity, prognosis, or response. NCI emphasizes that cancers—even within the same histologic type—can differ substantially in their molecular profiles. For research assay development, the biological meaning of a marker therefore depends on cancer type, specimen, tumor content, molecular context, treatment exposure, and the analytical platform used.
Research may focus on somatic mutations, copy-number changes, rearrangements, or other tumor-associated genomic alterations. A detected alteration should be interpreted within the specific cancer and study context rather than assumed to have the same significance across tumor types.
RT-qPCR can investigate expression of selected genes, fusion transcripts, splice variants, pathway modules, and treatment-associated transcriptional changes. Expression signatures require appropriate normalization and independent biological validation.
Proteins measured in tissue, blood, plasma, serum, or other matrices may provide information distinct from RNA abundance. ELISA and multiplex immunoassays address protein-level questions and require platform-specific validation.
Cancer biology reflects interactions among malignant cells, immune cells, stromal elements, extracellular signaling, vascular biology, and therapy. Bulk nucleic-acid measurements can therefore reflect both tumor-cell regulation and changes in cellular composition.
Research assays can be organized as mechanistic modules rather than rigid catalog panels. This makes target selection easier to justify and allows investigators to build around the biology of a specific cancer model.
Investigate selected growth-factor, kinase, transcriptional, and downstream signaling pathways that contribute to malignant-cell growth and survival.
Study pathways associated with cell-cycle control, genomic surveillance, growth restraint, and loss of tumor-suppressive signaling.
Explore genomic-stability, DNA-repair, replication-stress, and treatment-associated damage-response pathways.
Investigate pro-survival and programmed-cell-death pathways and their modulation by experimental therapies.
Study proliferative programs, checkpoint control, mitotic regulation, and growth-associated molecular responses.
Evaluate tumor responses to reduced oxygen availability and pathways involved in vascular development and adaptation.
Explore reactive-oxygen, antioxidant, metabolic-stress, and adaptive survival pathways relevant to cancer models.
Investigate extracellular-matrix, epithelial–mesenchymal, motility, adhesion, and tissue-remodeling programs where appropriate.
Compare pathway changes across untreated controls, treatment groups, dose levels, time points, responder models, and resistant models.
The analytical method should match the biomarker. Tumor DNA, RNA expression, and soluble-protein concentration are related biological layers but are not interchangeable measurements.
Best suited for: focused DNA/RNA research requiring sensitive, targeted molecular measurement.
Development principle: follow MIQE 2.0 concepts for preanalytics, assay specificity, amplification performance, controls, normalization, analytical range, data analysis, and transparent reporting.
Best suited for: focused quantitative measurement of one soluble protein or a small number of selected proteins.
Development principle: use fit-for-purpose ligand-binding assay validation covering working range, precision, selectivity, matrix effects, recovery/parallelism where meaningful, stability, and lot performance.
Best suited for: simultaneous measurement of multiple soluble proteins in tumor-immunology or systemic-response research.
Development principle: evaluate each analyte in the multiplex context and control matrix effects, dynamic-range differences, cross-talk, parallelism, protocol adherence, vendor/lot effects, and inter-run variability.
IMDNA research workflows can be adapted to solid-tumor biology, hematologic malignancies, immuno-oncology, and experimental therapy studies without implying that one marker set is universal across cancers.
Targeted investigation of tumor-associated molecular alterations and expression programs in solid-tumor research models.
Research into recurrent genetic alterations, fusion transcripts, mutations, expression programs, and molecular changes associated with hematologic malignancies.
Research into the molecular interface between malignant cells and immune pathways.
Compare molecular and protein profiles before, during, and after experimental treatment.
These examples are intended to illustrate research architecture—not to define universal cancer signatures. Target selection should be justified for the cancer type, specimen, biological model, and intended research use.
A defensible oncology biomarker program should be fit for purpose. Analytical validation should match the intended research use, and claims should remain limited to the specimen, platform, cancer context, and endpoint actually studied.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify cancer type/model, biological question, analyte, specimen, treatment context, comparator, and endpoint. | Determines whether DNA, RNA, protein, or combined measurements are scientifically appropriate. |
| 2. Select biomarkers mechanistically | Use authoritative literature, established cancer biology, discovery data, and prespecified hypotheses. | Mechanistic selection is more interpretable than assembling markers solely because they are measurable. |
| 3. Match analyte to technology | Use qPCR/RT-qPCR for targeted DNA/RNA, ELISA for focused proteins, and bead-based multiplex assays for multianalyte soluble-protein research. | RNA abundance, genomic alteration, and protein concentration answer different analytical questions. |
| 4. Define specimen & tumor context | Document tissue type, FFPE/fresh status, blood/bone marrow context, tumor-cell fraction where relevant, and preanalytical handling. | Tumor heterogeneity and cellular composition can materially affect measured molecular profiles. |
| 5. Characterize analytical performance | Evaluate specificity, precision, sensitivity/range, efficiency, matrix effects, multiplex compatibility, interference, and stability as appropriate. | Prevents technical artifacts from being misinterpreted as cancer biology. |
| 6. Establish controls & normalization | Use assay-appropriate negative, positive, process, calibration, and QC materials; validate reference-gene stability for expression studies. | Controls must address the actual failure modes of each platform. |
| 7. Verify biologically | Use well-characterized research materials, biological replication, appropriate controls, and longitudinal sampling where relevant. | Analytical validity alone does not establish biological or translational relevance. |
| 8. Validate independently | Lock candidate signatures or models and evaluate them in an independent cohort or sample set before broader claims are made. | Independent validation is required before generalizing a biomarker signature. |
Oncology biomarker research requires careful separation of analytical detection, tumor biology, clinical significance, and treatment relevance.
NCI notes that tumor markers can include proteins, gene mutations, gene-expression patterns, and other molecular features, but also emphasizes that marker interpretation depends on context and that no single biomarker approach is universally appropriate across cancers.
Therefore: IMDNA positions these assays for biomarker, pathway, molecular-profile, and translational research—not as universal diagnostic, prognostic, or treatment-selection algorithms.
A rigorous oncology assay program connects biological mechanism, specimen selection, biomarker choice, analytical technology, validation, and independent biological confirmation.
Each technology requires its own validation strategy. qPCR/RT-qPCR should follow current MIQE guidance; protein immunoassays require fit-for-purpose analytical characterization; and multiplex bead assays require analyte-level validation and standardized execution.
Control collection, fixation, storage, extraction, matrix, sample quality, tumor content, and longitudinal sampling conditions.
Evaluate assay specificity, amplification efficiency, analytical range, controls, reverse transcription, and normalization for the intended sample type.
Assess working range, precision, selectivity, matrix effects, parallelism/recovery where meaningful, stability, and lot performance.
Evaluate analyte-specific dynamic range, matrix sensitivity, cross-talk, protocol dependence, bead recovery, and inter-run variability.
Use platform-specific QC materials and validate reference genes rather than assuming constitutive stability across cancer models.
Separate discovery from confirmation and test candidate signatures outside the dataset in which they were developed.
Cancer research rarely fits one universal panel. IMDNA can develop integrated research solutions using qPCR/RT-qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies.
Whether your work focuses on solid tumors, leukemia, mutations, fusion transcripts, gene-expression signatures, DNA repair, tumor immunity, treatment response, resistance, biomarker discovery, or translational oncology, IMDNA can develop a focused assay strategy around the biomarkers and pathways that matter to your research question.